Bathetal
Table3.CumulativeOutcomeandSafetyatDays7,30,and90AfterEnrollment
Telmisartan(n 647)
7DaysDropouts(%)*Hemorrhagic
transformation(%)Cerebraledema(%)Strokerecurrence(%)MI(%)
Combinedvascular(%)Death(%)SAE(%)30DaysDropouts(%) mRS(mean,SD)mRS0–1vs2–6(%) Strokerecurrence(%)MI(%)
Combinedvascular(%)Death(%)SAE(%)
Mini-MentalStateExamination 30(%)90DaysDropouts(%)*Strokerecurrence(%)MI(%)
Combinedvascular(%)Death(%)SAE(%)
6(0.93)17(2.6)3(0.5)23(3.6)5(0.77)50(7.73)
6(0.84)14(2.0)1(0.1)19(2.7)6(0.84)39(5.47)
1.25(0.36,4.36)1.40(0.68,2.89)
…1.48(0.78,2.79)1.05(0.27,4.04)1.43(0.93,2.22)
4(0.621.3(1.1)401(64.5)13(2.01)2(0.31)17(2.63)4(0.62)29(4.48)190(32.0)
2(0.28)1.3(1.1)452(65.7)8(1.12)0(0.0)10(1.40)2(0.28)25(3.51)207(31.7)
3.98(0.52,30.2)
…1.00(0.77,1.29)1.89(0.77,4.62)
…2.07(0.93,4.63)
…1.30(0.75,2.25)1.02(0.80,1.31)
0(0.0)0(0.0)0(0.0)4(0.62)1(0.15)5(0.77)0(0.0)12(1.85)
1(0.14)3(0.42)0(0.0)5(0.70)0(0.0)6(0.84)1(0.14)10(1.40)
………0.88(0.24,3.31)
…0.95(0.28,3.16)
…1.37(0.59,3.21)
Placebo(n 713)
OR(95%CI)
TelmisartaninAcuteIschemicStroke3545
Figure2.Ordinalstroke(recurrenceandseverity)atday90,
comparisonbyMann–WhitneyUtest,P 0.42(note:themajorityofpatientswhodidnothaveaneventarenotshown,and3patientswitharecurrentstrokedidnothaveamRSrecorded;thenumbersofpatientswitheachoutcomeareshown).
N(%)ormean(SD)withOR(95%CI).Comparisonbybinarylogisticregressionormultipleregression(continuousvariables).SAEindicatesseriousadverseevents.
*Dropoutsarepatientslosttofollow-upatthetimepoint. Patientswithnoday30outcomedatawere

excluded.
havingarecurrenteventwaspresentinthosepatientswhowereenrolledduringtheacutephase.
TheresultsofthissubgroupanalysismaybecomparedwithpreviousstudiesofBP-loweringinacuteischemicstroke,especiallythosefromtheACCESStrial,15whichalsostudiedanoralARA(candesartan)inpatientswithacuteischemicstrokewithin72hoursofonset.However,thetrialsdifferedinseveralkeyrespects:size(ACCESSwasmuchsmallerwith339patients);timetorecruitment(ACCESShadameantimeof30hours);BPinclusioncriteria(ACCESSonlyincludedpatientswithseverelyelevatedBPandhadmeanBP189/99mmHg);presenceofotherantihypertensiveagents(patientsinACCESSwerenotusinganyotherBPdrugs);strokeseverity(thebaselineseverityisnotreportedintheACCESSarticlebutitislikelythatthestrokeswillhavebeenfarmoreseverewithsignificantlygreaterimpairment);location(patientsinACCESScamefromGermanyonly);lengthoftreatment(comparisonofcandesartanwithplacebo
inACCESSwasonlymadefor7dayswithpatientsinbothtreatmentgroupsreceivingcandesartanthereafterfor1year);effectoftreatmentonBP(candesartandidnotalterBPinACCESS);andresults(theprimaryoutcome,disabilityat3months,inACCESSwasneutral,althoughtreatmentwithcandesartanwasassociatedwithasignificantreductioninasecondaryoutcome,comprisingthecumulative12-monthmortalityandvascularevents).15
TakingthesimilaritiesanddifferencesbetweenACCESSandPRoFESS,theapparentdiscrepanciesintheirresultsmaysimplyreflectafalse-positivefindinginthesmallACCESStrial.Additionally,thefailuretoshowbeneficialeffectsoftelmisartanmayreflectthatpatientshadonlymildhyperten-sionandmildstroke.Nevertheless,thissubgroupanalysisofPRoFESSisthefirsttoourknowledgetotestwhetheritissafeforpatientswithacutemildstroketohavetheirBPactivelylowered.BecausechronicloweringofBPreducesstrokerecurrence,23,24thepresentresultssuggestitissafetostartsuchtreatmentacutely,particularlyifbasedonanangiotensin-modifyingdrug.Further,itispossiblethattheseresultscanbeextrapolatedtopatientswithTIAforwhichnotrialshavebeenperformedtodateand,possibly,nonearelikely.SeveralcaveatsexistforthisPRoFESSsubgroupanalysis.First,theresultscomefromasubgroupofpatientsenteredintoalargesecondarypreventiontrialsuchthatpatientcharacteristicsreflecttheinclusioncriteriaforastudyofvascularprophylaxisratherthanacuteintervention.Asaresult,thetrialwasnotdesignedtoexplicitlytesttheeffectofloweringBPinacutestroke.Second,theinclusioncriteriaincludedneurologicalstability,whichisusuallyabsentinacutestroke,andmeansthatnopatientswererecruitedduringthehyperacutephase( 6hoursofonset)ofstroke.Third,thesamplesizewastoosmalltoreliablydetecttheeffectsoftelmisartanonfunctionaloutcomeorsecondaryprevention.TheongoingSCASTtrial(doc.guandang.net)ofcandesar-tanin2500patientswillextendtheexistingdatafromACCESSandPRoFESSonloweringBPinacuteischemicstrokewithARA.OtherlargetrialsarealsoassessingthemanagementofBPinacutestroke,includingENOS
(Prevention Regimenf or Effectively Avoiding Second Strokes,PROFESS)的结果,认为卒中后即刻给予血管紧张素受体拮抗剂替米沙坦不能对复发性缺血事件提供明显的保护作用...
结论 凝视麻痹反向变化预示着病情加重和不良预后, 脑干功能受累可能是出现此眼征的病理基础 。 【关键词】 凝视麻痹; 急性脑卒中; 预后 高龄和意识障碍是卒中患者...
卒中 一过性脑缺血发作 伴靶器官损害的高危2型糖尿...ACEI或ARB可改善此类患者的预后 –伴ST段抬高心肌...激活作用 替米沙坦 厄贝沙坦 坎地沙坦 缬沙坦 奥...
能有效地改善急性脑梗死的神经功能 缺损及长期生存...存在是缺血性卒中复发,尤其是早期复发的独立危险因素...研究提示缺血性卒中急性期使用他汀可能改善卒中预后 ?...
如要投诉违规内容,请到百度文库投诉中心;如要提出功能问题或意见建议,请点击此处...更多>>目的:研究急性缺血性卒中患者脑血管狭窄与卒中再发和预后的关系。方法:...
停用阿托伐他汀对缺血性脑卒中复发及预后的影响_基础...1 9? 节, 详细作用 今日推荐 50份文档 ...阿托伐他汀在急性脑卒中... 6人阅读 3页 1...
早期康复对急性脑卒中偏瘫患者预后的影响_专业资料。目的探讨早期康复对急性脑卒中...于治疗前、治疗后1个月及治疗后1年对患者进行评估,采用神经功能缺损程度(NIHSS...
请到百度文库投诉中心;如要提出功能问题或意见建议,...· 究方法 ,观察脑卒中患者急性期血压与预后的关系...由于复发病例数太少 , 在后 面的预后评价中未作分析...
在英国每年发生 110 000例首次卒中和 30 000 例复发卒中 , 有 10 000 例...的运动 、 感觉或皮层功能失调和偏盲 ,通常用于 诊断某些临床亚型并提示预后 。...
药物在急性缺血性脑卒中的早期应用杨琼,张新宇,李小刚 关键词:脑缺血;卒中;降...预处理降低脑卒中复发、改善预后,而不 良反应的发生很少,差异无统计学意义〔6...
热门文档